MapLight Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$27.30
−$2.46 (−8.27%) 4:00 PM ET
Pre-market$27.34
+$0.04 (+0.15%) 5:51 AM ET
Prev closePrevC$29.76
OpenOpen$29.76
Day highHigh$30.12
Day lowLow$26.99
VolumeVol467,130
Avg volAvgVol311,870
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.24B
P/E ratio
1.42
EPS
19.29
Sector
Healthcare
AI report sections
MIXED
MPLT
MapLight Therapeutics, Inc. Common Stock
MPLT exhibits upward price momentum over the past 1–3 months with the latest close near the upper end of its 52-week range and above key moving averages. Technical indicators such as RSI and MACD point to constructive but not extreme bullish conditions, while pattern signals highlight recent breakout behavior alongside moderate volatility and a notable short-volume ratio. Limited disclosed fundamentals and valuation metrics constrain longer-horizon assessment, placing more emphasis on clinical and news catalysts as well as the current short-interest profile.
AI summarized at 12:24 AM ET, 2026-04-01
AI summary scores
INTRADAY:68SWING:72LONG:55
Volume vs average
Intraday (cumulative)
+80% (Above avg)
Vol/Avg: 1.80×
RSI
55.40(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.02 (Strong)
MACD: -0.18 Signal: -0.20
Short-Term
-0.10 (Weak)
MACD: 0.59 Signal: 0.69
Long-Term
-0.20 (Weak)
MACD: 2.06 Signal: 2.26
Intraday trend score
52.86
LOW51.86HIGH62.86
Latest news
MPLT•3 articles•Positive: 2Neutral: 1Negative: 0
NeutralThe Motley Fool• Sarah Sidlow
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
MapLight Therapeutics' CFO Setia Vishwas sold 36,371 shares worth approximately $1.02 million in May 2026 through a pre-arranged Rule 10b5-1 trading plan. The sale reduced his direct holdings by 9.3%, though he retains 356,256 shares. The article notes this shouldn't be interpreted as a lack of confidence since it was part of a predetermined trading plan. MapLight, a clinical-stage biotech company focused on CNS disorders, has seen its stock gain 70.8% over the past year but continues to report deepening losses as it advances its pipeline.
The CFO's sale was executed through a pre-arranged trading plan, which the article explicitly states should not be interpreted as a signal of lost confidence or insider knowledge about future performance. While the company shows promising stock gains (70.8% YoY) and an expanded pipeline, it remains unprofitable with deepening losses. The neutral sentiment reflects the mixed signals: positive clinical progress offset by financial challenges and the non-indicative nature of the insider sale.
PositiveGlobeNewswire Inc.• Na
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.
The company reported accelerated enrollment in its Phase 2 trials ahead of schedule, demonstrating strong execution and momentum in clinical development. The narrowed timing guidance to Q3 2026 for both ZEPHYR and IRIS trials indicates progress and operational efficiency, which are positive indicators for investors and stakeholders.
PositiveBenzinga• Globe Newswire
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
MapLight Therapeutics completed its initial public offering of 16,962,500 shares at $17.00 per share, raising $296.3 million. The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with a lead product candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis.
Successfully completed IPO, raised significant capital ($296.3M), trading on Nasdaq, advancing clinical-stage drug development for neurological disorders
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
